Xintela AB (XINT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Xintela AB (XINT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8295
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Xintela AB (Xintela) is a biomedical company that develops treatment for cartilage damage and brain tumors. The company’s technology includes Xinmark, a patented marker technology developed to identify and select certain types of tumor cells, which can develop into cartilage cells. It also provides analytical test such as XACT (Xintela Assay for Cell Therapy), used for quality assurance of methods and cells. Xintela’s analytical test finds application in research and development activities for stem cell products. It develops therapeutic antibodies, which bind to cancer cells. The company conducts its research in the fields of regenerative medicine and cancer with significance on cartilage damage such as osteoarthritis and brain cancer. Xintela is headquartered in Lund, Sweden.

Xintela AB (XINT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xintela AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Xintela AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Xintela AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Xintela Raises US$0.9 Million In Venture Financing 10
Partnerships 11
CO.DON to Form Joint Venture with Xintela 11
Xintela Enters into Collaboration Agreement with CellSeed 12
Xintela to Enter into Agreement with Co.don 13
Licensing Agreements 14
Xintela Licenses Human Antibody Technology for Cancer Therapy 14
Equity Offering 15
Xintela Raises USD1.1 Million in Private Placement of Shares 15
Xintela Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 16
Xintela Completes Underwriter’s Exercise of Over-Allotment Option of Rights Offering for USD4 Million 17
Xintela AB – Key Competitors 18
Xintela AB – Key Employees 19
Xintela AB – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Strategy And Business Planning 21
Aug 29, 2018: Xintela to spin out oncology business 21
Sep 11, 2017: Xintela building own GMP-facility for stem cell production 22
Corporate Communications 23
Aug 29, 2018: Xintela appoints Sven Kili as Chief Medical Officer 23
Oct 17, 2017: Keld Sondergaard leaves Xintela’s Board of Directors 24
Product News 25
Dec 29, 2017: Xintela licenses human antibody technology for cancer therapy 25
Apr 17, 2018: Xintela develops unique methods in stem cell therapy for the brain and broadens patent portfolio 26
Other Significant Developments 27
Aug 21, 2018: Xintela: Significant progress in development programs 27
Apr 26, 2018: Xintela’s GMP facility is completed and being prepared for production and clinical trials 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Xintela AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xintela AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xintela AB, Deals By Therapy Area, 2012 to YTD 2018 8
Xintela AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Xintela Raises US$0.9 Million In Venture Financing 10
CO.DON to Form Joint Venture with Xintela 11
Xintela Enters into Collaboration Agreement with CellSeed 12
Xintela to Enter into Agreement with Co.don 13
Xintela Licenses Human Antibody Technology for Cancer Therapy 14
Xintela Raises USD1.1 Million in Private Placement of Shares 15
Xintela Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 16
Xintela Completes Underwriter’s Exercise of Over-Allotment Option of Rights Offering for USD4 Million 17
Xintela AB, Key Competitors 18
Xintela AB, Key Employees 19

List of Figures
Xintela AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xintela AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xintela AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Xintela AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xintela AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Xintela AB (XINT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • GenePOC Inc-医療機器分野:企業M&A・提携分析
    Summary GenePOC Inc (GenePOC), a subsidiary of Debiopharm Group is a medical device company that develops rapid molecular devices for providing targeted therapy. The company offers on-the-spot diagnostic devices for achieving optimal patient management. It offers diagnostic instruments based on a no …
  • CEL-SCI Corp (CVM):企業の財務・戦略的SWOT分析
    CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Pacific Biosciences of California Inc (PACB):製薬・医療:M&Aディール及び事業提携情報
    Summary Pacific Biosciences of California Inc (Pacific Biosciences) designs, develops, and manufactures sequencing instruments for solving complex genetic abnormalities. The company’s product portfolio comprises proprietary Phospholinked nucleotides, sequencing systems, analytical software and consu …
  • Avantec Vascular Corp:製品パイプライン分析
    Summary Avantec Vascular Corp (Avantec Vascular), a subsidiary of Goodman Co Ltd is a medical device company that develops cardiovascular interventional and peripheral vascular devices. The company's products comprise balloon catheter, aspiration catheter, device delivery system, micro catheter, gui …
  • Consumers Energy Co (CMS PR B):企業の財務・戦略的SWOT分析
    Consumers Energy Co (CMS PR B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ypsomed Holding AG (YPSN)-医療機器分野:企業M&A・提携分析
    Summary Ypsomed Holding AG (Ypsomed) is a medical device company. It designs, develops and manufactures injection systems. Its offers pen injectors, autoinjectors, dual chamber pens and other custom products. The company also offers contract manufacturing, industrial design, human factors engineerin …
  • Honkarakenne Oyj (HONBS):企業の財務・戦略的SWOT分析
    Honkarakenne Oyj (HONBS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Al Hassan Engineering Co (HECI):企業の財務・戦略的SWOT分析
    Al Hassan Engineering Co (HECI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • IntelliCell BioSciences Inc:企業の戦略的SWOT分析
    IntelliCell BioSciences Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Sypris Solutions, Inc.:戦略・SWOT・企業財務分析
    Sypris Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sypris Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Electricity Generating Public Co Ltd:企業の発電所・SWOT分析2018
    Electricity Generating Public Co Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Instituto Costarricense de Electricidad:企業の戦略的SWOT分析
    Instituto Costarricense de Electricidad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Patheon NV:戦略・SWOT・企業財務分析
    Patheon NV - Strategy, SWOT and Corporate Finance Report Summary Patheon NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Teijin Pharma Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Teijin Pharma Ltd (Teijin Pharma), a subsidiary of Teijin Ltd develops, manufactures and markets pharmaceutical and home healthcare products. The company offers a range of pharmaceutical products for the treatment of bone and joint diseases, respiratory diseases and cardiovascular and metabo …
  • Genzyme Corp:医療機器:M&Aディール及び事業提携情報
    Summary Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty care treatments targeting rare diseases, oncology, immunology and multiple sclerosis. It offers products for the treatment of indications including various forms of cancer, mucopolysaccharidosi …
  • Carlisle Companies Incorporated:企業のM&A・事業提携・投資動向
    Carlisle Companies Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Carlisle Companies Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • BioMoti Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary BioMoti Ltd (BioMoti) is a pharmaceutical company that offers cancer therapeutics that develops platform drug delivery technologies. The company provides products such as Oncojans a class of immunotherapeutic drug-loaded particles to target and gain entry into the tumour vasculature and canc …
  • Lisi Aerospace SAS:企業の戦略・SWOT・財務分析
    Lisi Aerospace SAS - Strategy, SWOT and Corporate Finance Report Summary Lisi Aerospace SAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Aevi Genomic Medicine Inc (GNMX):医療機器:M&Aディール及び事業提携情報
    Summary Aevi Genomic Medicine Inc (Aevi), formerly Medgenics Inc is a research and development company that discovers and develops novel therapies for pediatric onset and life-altering diseases.The company provides pipeline products such as AEVI-001 and AEVI-002. Its lead product AEVI-001, is a glut …
  • Independence Group NL:企業のM&A・事業提携・投資動向
    Independence Group NL - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Independence Group NL Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆